Freeline Therapeutics (FRLN) Scheduled to Post Earnings on Wednesday

Freeline Therapeutics (NASDAQ:FRLN) is scheduled to be posting its quarterly earnings results on Wednesday, November 22nd.

Freeline Therapeutics Stock Up 14.7 %

Freeline Therapeutics stock opened at $5.76 on Tuesday. Freeline Therapeutics has a 52 week low of $2.11 and a 52 week high of $10.20. The firm has a market cap of $25.00 million, a price-to-earnings ratio of -0.69 and a beta of 0.39. The business’s 50-day moving average price is $4.43 and its 200 day moving average price is $3.77.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on FRLN. Wedbush lowered shares of Freeline Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the company from $8.00 to $5.00 in a report on Wednesday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Freeline Therapeutics in a report on Thursday, August 17th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in FRLN. Acadian Asset Management LLC purchased a new stake in Freeline Therapeutics in the 1st quarter worth $30,000. Northern Trust Corp purchased a new stake in shares of Freeline Therapeutics during the second quarter worth about $40,000. Federated Hermes Inc. raised its position in shares of Freeline Therapeutics by 50.0% during the 1st quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after purchasing an additional 20,000 shares during the last quarter. Renaissance Technologies LLC increased its stake in Freeline Therapeutics by 17.4% during the 1st quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock worth $105,000 after buying an additional 34,210 shares in the last quarter. Finally, UBS Group AG purchased a new stake in Freeline Therapeutics during the 1st quarter worth approximately $565,000. Hedge funds and other institutional investors own 46.26% of the company’s stock.

Freeline Therapeutics Company Profile

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.